260 related articles for article (PubMed ID: 12562237)
61. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
[TBL] [Abstract][Full Text] [Related]
62. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
[TBL] [Abstract][Full Text] [Related]
63. [Prognostic significance of proteins expression by immunohistochemical method in diffuse large B cell lymphoma].
Yu WJ; Cao LH; Wang JH; Wang ZM; Qian WB; Tong HY; Meng HT; Mai WY; Mao LP; Qian JJ; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):784-788. PubMed ID: 29081196
[No Abstract] [Full Text] [Related]
64. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
65. Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.
Kim SH; Cheong JW; Park KH; Kim TS; Yang WI
Arch Pathol Lab Med; 2007 Mar; 131(3):457-67. PubMed ID: 17516749
[TBL] [Abstract][Full Text] [Related]
66. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
[TBL] [Abstract][Full Text] [Related]
67. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
68. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
69. [Primary diffuse large B-cell lymphoma of central nervous system belongs to activated B-cell-like subgroup: a study of 47 cases].
Cheng J; Tu P; Shi QL; Zhou HB; Zhou ZY; Zhao YC; Ma HH; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):384-9. PubMed ID: 19031717
[TBL] [Abstract][Full Text] [Related]
70. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.
Chang CC; McClintock S; Cleveland RP; Trzpuc T; Vesole DH; Logan B; Kajdacsy-Balla A; Perkins SL
Am J Surg Pathol; 2004 Apr; 28(4):464-70. PubMed ID: 15087665
[TBL] [Abstract][Full Text] [Related]
71. [Primary central nervous system diffuse large B cell lymphoma: a clinicopathologic and molecular study].
Ma ZP; Ainiwaer B; Liu ZY; Shi XL; Cui WL; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Nov; 45(11):762-768. PubMed ID: 27821230
[No Abstract] [Full Text] [Related]
72. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
[TBL] [Abstract][Full Text] [Related]
73. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature.
Bhagavathi S; Micale MA; Les K; Wilson JD; Wiggins ML; Fu K
Am J Surg Pathol; 2009 Oct; 33(10):1463-9. PubMed ID: 19675454
[TBL] [Abstract][Full Text] [Related]
74. Central nervous system lymphoma in immunocompetent patients: the North Shore-Long Island Jewish Health System experience.
Zhang X; Chen QH; Farmer P; Nasim M; Demopoulos A; Devoe C; Ranjan T; Eisenberg MB; Schulder M; Bi C; Li JY
J Clin Neurosci; 2013 Jan; 20(1):75-9. PubMed ID: 23098391
[TBL] [Abstract][Full Text] [Related]
75. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
76. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
77. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
[TBL] [Abstract][Full Text] [Related]
78. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
79. Expression of oncogenic molecules in primary central nervous system lymphomas in immunocompetent patients.
Nozaki M; Tada M; Mizugaki Y; Takada K; Nagashima K; Sawamura Y; Abe H
Acta Neuropathol; 1998 May; 95(5):505-10. PubMed ID: 9600597
[TBL] [Abstract][Full Text] [Related]
80. Clinicopathologic features and prognostic analysis of Waldeyer ring B-cell lymphoma.
Ma Z; Shi Y; Pang X; Li X; Cui W; Zhang W
Medicine (Baltimore); 2020 Jan; 99(2):e18670. PubMed ID: 31914056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
